Standout Papers

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes 2018 2026 2020 2023 4.1k
  1. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes (2018)
    Stephen D. Wiviott, Itamar Raz et al. New England Journal of Medicine
  2. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials (2018)
    Thomas A. Zelniker, Stephen D. Wiviott et al. The Lancet
  3. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus (2019)
    Thomas A. Zelniker, Stephen D. Wiviott et al. Circulation

Immediate Impact

4 from Science/Nature 91 standout
Sub-graph 1 of 13

Citing Papers

Albuminuria in Cardiovascular, Kidney, and Metabolic Disorders: A State-of-the-Art Review
2025 Standout
Causal machine learning for predicting treatment outcomes
2024 Standout
64 intermediate papers

Works of Avivit Cahn being referenced

Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes
2021
Prediction of progression from pre‐diabetes to diabetes: Development and validation of a machine learning model
2020
and 19 more

Author Peers

Author Last Decade Papers Cites
Avivit Cahn 7371 3007 2872 111 8.8k
Greg Fulcher 7548 2847 3312 62 9.2k
Thomas A. Zelniker 6545 2744 2725 67 8.4k
Mehul Desai 7621 3202 3333 49 9.2k
Eri Kato 5783 2397 2396 45 7.2k
B Charbonnel 6864 3248 2763 236 9.4k
Stefan Hantel 9082 3893 4555 62 13.3k
Julia Kuder 4736 1865 3409 59 8.4k
Michaela Mattheus 11062 4439 4754 80 13.1k
Steven P. Marso 8596 3303 3068 72 10.7k
Saul Genuth 7138 2264 2124 111 11.5k

All Works

Loading papers...

Rankless by CCL
2026